Skip to content

Study · Observational study · n = 115 · 2026

10 results

A real-world study of tirzepatide for weight loss in adults without diabetes mellitus.

Angelopoulos N, Androulakis I, Rizoulis A, Boniakos A, Fousteris E, Mentzelopoulou V, Petkova V, Paparodis R, Zianni D, Florakis D, Korakovouni A, Mouslech Z, Livadas S, Tzoulis P

International journal of obesity (2005)8 Dec 2025Cited by 1 (Europe PMC)

PMID41354867 (opens in a new tab)DOI10.1038/s41366-025-01986-0 (opens in a new tab)PepBankPUB-41354867
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with obesity without diabetes, low-dose tirzepatide was followed by a mean body weight decrease of 8.2 kg (7.3%) over 12 weeks.

    In plain wordsIn adults with obesity but no diabetes, average body weight fell by 8.2 kg after 12 weeks of low-dose tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight change at week 12
    Study

    n = 115

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.5 mg weekly for 4 weeks, then 5 mg weekly · 12 weeksAs given in this study (human).

    Measurements

    Body weight decrease
    8.2 kg
    week 12

    Source sentences

    Summary
    Mean body weight decreased by 8.2 ± 4.9 kg (-7.3% ±4.4%)
    1 context sentence
    Summary · context
    In this prospective multicentre observational study, 115 adults with obesity but without diabetes were treated with tirzepatide 2.5 mg weekly for 4 weeks, titrated to 5 mg for a total of 12 weeks.
  2. 02HumanObservational studyEfficacy outcome

    In adults with obesity without diabetes, low-dose tirzepatide was followed by a BMI reduction of 2.8 kg/m² over 12 weeks.

    In plain wordsIn adults with obesity but no diabetes, BMI fell by 2.8 kg/m² after 12 weeks of low-dose tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBMI change at week 12
    Study

    n = 115

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.5 mg weekly for 4 weeks, then 5 mg weekly · 12 weeksAs given in this study (human).

    Measurements

    BMI reduction
    2.8 kg/m²
    week 12

    Source sentences

    Summary
    with a BMI reduction of 2.8 ± 1.7 kg/m²
    1 context sentence
    Summary · context
    In this prospective multicentre observational study, 115 adults with obesity but without diabetes were treated with tirzepatide 2.5 mg weekly for 4 weeks, titrated to 5 mg for a total of 12 weeks.
  3. 03HumanObservational studyEfficacy outcome

    In adults with obesity without diabetes, 46.1% reached at least 5% weight loss after 12 weeks of low-dose tirzepatide.

    In plain wordsIn adults with obesity but no diabetes, 46.1% lost at least 5% of body weight in 12 weeks on low-dose tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseProportion with at least 5% weight loss
    Study

    n = 115

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.5 mg weekly for 4 weeks, then 5 mg weekly · 12 weeksAs given in this study (human).

    Measurements

    Responders with ≥5% weight loss
    46.1%
    week 12

    Source sentences

    Summary
    46.1% achieved ≥5% weight loss.
    1 context sentence
    Summary · context
    In this prospective multicentre observational study, 115 adults with obesity but without diabetes were treated with tirzepatide 2.5 mg weekly for 4 weeks, titrated to 5 mg for a total of 12 weeks.
  4. 04HumanObservational studyEfficacy outcome

    In adults with obesity without diabetes, HbA1c fell from 5.6% to 5.4% after 12 weeks of low-dose tirzepatide.

    In plain wordsIn adults with obesity but no diabetes, HbA1c, a blood sugar marker, fell slightly after 12 weeks of low-dose tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c change
    Study

    n = 115

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.5 mg weekly for 4 weeks, then 5 mg weekly · 12 weeksAs given in this study (human).

    Measurements

    HbA1c baseline
    5.6%
    baseline
    HbA1c week 12
    5.4%
    week 12

    Source sentences

    Summary
    HbA1c decreased from 5.6 ± 0.4% to 5.4 ± 0.3%
    1 context sentence
    Summary · context
    In this prospective multicentre observational study, 115 adults with obesity but without diabetes were treated with tirzepatide 2.5 mg weekly for 4 weeks, titrated to 5 mg for a total of 12 weeks.
  5. 05HumanObservational studyEfficacy outcome

    In adults with obesity without diabetes, LDL cholesterol fell from 113 to 106 mg/dL after 12 weeks of low-dose tirzepatide.

    In plain wordsIn adults with obesity but no diabetes, LDL cholesterol fell after 12 weeks of low-dose tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseLDL cholesterol change
    Study

    n = 115

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    2.5 mg weekly for 4 weeks, then 5 mg weekly · 12 weeksAs given in this study (human).

    Measurements

    LDL cholesterol baseline
    113 mg/dL
    baseline
    LDL cholesterol week 12
    106 mg/dL
    week 12

    Source sentences

    Summary
    LDL cholesterol from 113 ± 30.4 to 106 ± 28 mg/dL
    1 context sentence
    Summary · context
    In this prospective multicentre observational study, 115 adults with obesity but without diabetes were treated with tirzepatide 2.5 mg weekly for 4 weeks, titrated to 5 mg for a total of 12 weeks.
  6. 06HumanObservational studyEfficacy outcome

    In adults with obesity without diabetes, triglycerides fell from 123.6 to 119.2 mg/dL after 12 weeks of low-dose tirzepatide.

    In plain wordsIn adults with obesity but no diabetes, triglycerides fell slightly after 12 weeks of low-dose tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseTriglycerides change
    Study

    n = 115

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    2.5 mg weekly for 4 weeks, then 5 mg weekly · 12 weeksAs given in this study (human).

    Measurements

    Triglycerides baseline
    123.6 mg/dL
    baseline
    Triglycerides week 12
    119.2 mg/dL
    week 12

    Source sentences

    Summary
    triglycerides from 123.6 ± 56.1 to 119.2 ± 44.5 mg/dL
    1 context sentence
    Summary · context
    In this prospective multicentre observational study, 115 adults with obesity but without diabetes were treated with tirzepatide 2.5 mg weekly for 4 weeks, titrated to 5 mg for a total of 12 weeks.
  7. 07HumanObservational studyEfficacy outcome

    In adults with obesity without diabetes, HDL cholesterol remained unchanged after 12 weeks of low-dose tirzepatide.

    In plain wordsIn adults with obesity but no diabetes, HDL cholesterol did not change after 12 weeks of low-dose tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeHDL cholesterol change
    Study

    n = 115

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    2.5 mg weekly for 4 weeks, then 5 mg weekly · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    while HDL cholesterol and eGFR remained unchanged.
    1 context sentence
    Summary · context
    In this prospective multicentre observational study, 115 adults with obesity but without diabetes were treated with tirzepatide 2.5 mg weekly for 4 weeks, titrated to 5 mg for a total of 12 weeks.
  8. 08HumanObservational studyEfficacy outcome

    In adults with obesity without diabetes, eGFR remained unchanged after 12 weeks of low-dose tirzepatide.

    In plain wordsIn adults with obesity but no diabetes, kidney filtration (eGFR) did not change after 12 weeks of low-dose tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeeGFR change
    Study

    n = 115

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    2.5 mg weekly for 4 weeks, then 5 mg weekly · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    while HDL cholesterol and eGFR remained unchanged.
    1 context sentence
    Summary · context
    In this prospective multicentre observational study, 115 adults with obesity but without diabetes were treated with tirzepatide 2.5 mg weekly for 4 weeks, titrated to 5 mg for a total of 12 weeks.
  9. 09HumanObservational studySafety outcome

    In adults with obesity without diabetes, nausea was the most common adverse event, in 7.8% on low-dose tirzepatide.

    In plain wordsIn adults with obesity but no diabetes, 7.8% had nausea on low-dose tirzepatide, the most common side effect.

    Peptide
    Tirzepatide
    Outcome
    Not applicableNausea
    Study

    n = 115

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    2.5 mg weekly for 4 weeks, then 5 mg weekly · 12 weeksAs given in this study (human).

    Measurements

    Nausea incidence
    7.8%

    Source sentences

    Summary
    Nausea was the most common adverse event (7.8%)
    1 context sentence
    Summary · context
    In this prospective multicentre observational study, 115 adults with obesity but without diabetes were treated with tirzepatide 2.5 mg weekly for 4 weeks, titrated to 5 mg for a total of 12 weeks.
  10. 10HumanObservational studySafety outcome

    In adults with obesity without diabetes, 10.4% stopped low-dose tirzepatide, mainly people previously treated with GLP-1 receptor agonists.

    In plain wordsIn adults with obesity but no diabetes, 10.4% stopped tirzepatide, mostly people who had used GLP-1 drugs before.

    Peptide
    Tirzepatide
    Outcome
    Not applicableTreatment discontinuation
    Study

    n = 115

    Outcome group
    Adverse events · Whole body
    Studied dose
    2.5 mg weekly for 4 weeks, then 5 mg weekly · 12 weeksAs given in this study (human).

    Measurements

    Discontinuation
    10.4%

    Source sentences

    Summary
    treatment discontinuation occurred in 10.4%, mainly among individuals previously treated with GLP-1 receptor agonists.
    1 context sentence
    Summary · context
    In this prospective multicentre observational study, 115 adults with obesity but without diabetes were treated with tirzepatide 2.5 mg weekly for 4 weeks, titrated to 5 mg for a total of 12 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.